Compare IRIX & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRIX | LRE |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 17.9M |
| IPO Year | 1996 | 2022 |
| Metric | IRIX | LRE |
|---|---|---|
| Price | $0.71 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.1K | 8.4K |
| Earning Date | 05-12-2026 | 07-30-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,593,000.00 | N/A |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $1.00 |
| 52 Week High | $1.65 | $2.86 |
| Indicator | IRIX | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 30.29 | 41.81 |
| Support Level | N/A | $1.18 |
| Resistance Level | $1.16 | $1.36 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 4.14 | 5.26 |
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.